- Global Pharma News & Resources

Nordic Nanovector Announces Changes to its Executive Management Team

Nordic Nanovector ASA (OSE: NANO) today announces changes to its Executive Management Team. As a result of the cost-saving initiatives announced on 2 April 2020, the Board of Directors of Nordic Nanovector has restructured the senior management team. The restructuring has resulted in the number of executives being reduced from nine to seven.


Malene Brondberg, Vice President Investor Relations and Corporation Communications, has been appointed CFO, effective 1 May, reporting to Lars Nieba, interim CEO. Malene Brondberg will in her new role as CFO be responsible for the areas Finance, Human Resources and Investor Relations.


Tone Kvåle and Rita Dege leave from their respective roles as Chief Financial Officer and Chief Human Resources Officer as of 1 May 2020.


Ms. Brondberg joined Nordic Nanovector in February 2018 bringing over 20 years’ operational experience in the financial services sector. Her career has included Global Head of Research managing a team of 67 people and member of the Executive Committee of the Nordic investment bank ABG Sundal Collier. Since 2011, Ms. Brondberg has worked as a management consultant within the financial sector, acting as an advisor in relation to investor relations and funding, and has held various interim CEO, COO and Head of Compliance/HR/Finance management positions. 


For further information, please contact:

IR enquiries

Jan H. Egberts, Chairman of Nordic Nanovector

Tel: +31 614672518



Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)

Tel: +44 203 926 8535



About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.


Further information can be found at


Editor Details

  • Company:
    • Nordic Nanovector
  • Name:
    • Nordic Nanovector
Last Updated: 05-May-2020